The efficacy of these treatments is well documented, and they have proven to improve outcomes in patients; however, the side effects of these medications, specifically the association with peripheral neuropathy development, has not been well studied in checkpoint inhibitors such as PD-1 inhibitors (including nivolumab, pembrolizumab, lambrolizumab and pidilizumab). The gene discussed is PDCD1; the disease is peripheral neuropathy.